BackFresenius Medical Care AG Overview

Fresenius Medical Care AG Common Stock

Latest common stock for FMS: $290M.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$293.41M
0.00% YoYΔ $0.00 vs prior year quarter

Peer average

Loading

Fresenius Medical Care AG Common Stock History

Loading

Fresenius Medical Care AG vs. peers: Common Stock Comparison

Loading

Fresenius Medical Care AG Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Fresenius Medical Care AG (FMS) FAQ

Fresenius Medical Care AG's common stock stands at $290M as of March 2026. That compares with $290M in the prior-year period — up 0.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Fresenius Medical Care AG reported $290M in common stock versus $290M a year earlier — essentially flat versus a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $290M in the prior-year period — up 0.0% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Fresenius Medical Care AG's common stock evolved across reporting periods, while the comparison chart places FMS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, common stock is commonly used to spot outliers. Fresenius Medical Care AG's reading of $290M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.